MNOV · MediciNova

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

4275 Executive Square, La Jolla, CA, 92037, United States
Biotechnology
Healthcare

Market Cap

67.11M

52 Wk Range

$1.22 - $3.90

Previous Close

$1.27

Open

$1.27

Volume

49,013

Day Range

$1.27 - $1.32

Enterprise Value

35.91M

Cash

29.26M

Avg Qtr Burn

-2.385M

Insider Ownership

2.76%

Institutional Own.

26.18%

Qtr Updated

Sep 30th 2026